Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Dalbavancin 500mg Powder for infusion.
This niche antibiotic has been developed based on the reference brand Xydalba (EU) and is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
With the addition of Dalbavancin, we have secured a niche and difficult to produce pharmaceutical with limited competition. In addition, we are also strengthening our strategic partnership with one of our trusted partners.” says Mr Lars Minor CEO of Newbury
Regulatory filling will take place in the near future and launch of this medicine is planned in Sweden where the total annual value of the market is estimated to be 3,5 MEUR according to DLMI Nordic Pharma Insights.
Dalbavancin Powder is replacing a previously signed product, Daptomycin, from the same partner. The commercial attractiveness is judged to be better for Dalbavancin and no additional in-licensing fees will be paid.
